Literature DB >> 8514034

Renal sodium retention during upright posture in preascitic cirrhosis.

M Bernardi1, C Di Marco, F Trevisani, L Fornalè, P Andreone, C Cursaro, M Baraldini, A Ligabue, M R Tamè, G Gasbarrini.   

Abstract

BACKGROUND: Renal sodium handling in preascitic cirrhosis is not clearly defined. This issue was addressed by evaluating renal sodium metabolism with different postures.
METHODS: Renal function and plasma atrial natriuretic factor (ANF), aldosterone, and norepinephrine levels were determined after 2 hours of standing and 30, 60, and 120 minutes after taking up the supine position in 10 patients and 10 healthy subjects.
RESULTS: When upright, patients' glomerular filtration rate and plasma ANF and norepinephrine levels did not differ from those of controls. Conversely, renal sodium excretion was reduced. Plasma aldosterone levels, which were slightly elevated, inversely correlated with renal sodium excretion. In the supine position, natriuresis increased by 308% +/- 99% in patients and 113% +/- 29% in controls (P = 0.016), so that it no longer differed between the two groups. Plasma norepinephrine and aldosterone levels decreased to a similar extent in controls and cirrhotics, whereas the increase in plasma ANF level was greater in patients. The changes in natriuresis correlated with those in plasma ANF levels and plasma aldosterone-ANF ratios in both controls and patients.
CONCLUSIONS: Aldosterone-dependent sodium retention develops in preascitic cirrhosis during standing. The supine position is the means whereby standing-induced sodium retention can be balanced.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8514034     DOI: 10.1016/0016-5085(93)90025-8

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  12 in total

1.  Cardiac response to exercise in cirrhosis.

Authors:  R H Wachsberg
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

Review 2.  Renal dysfunction in cirrhosis: diagnosis, treatment and prevention.

Authors:  Elaine Yeung; Elaine Yong; Florence Wong
Journal:  MedGenMed       Date:  2004-12-02

3.  Reduced activity of 11 beta-hydroxysteroid dehydrogenase in patients with cholestasis.

Authors:  C Quattropani; B Vogt; A Odermatt; B Dick; B M Frey; F J Frey
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

4.  Renal tubular events following passage from the supine to the standing position in patients with compensated liver cirrhosis: loss of tubuloglomerular feedback.

Authors:  G Sansoè; A M Biava; S Silvano; A Ferrari; F Rosina; A Smedile; A Touscoz; L Bonardi; M Rizzetto
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

5.  Natriuretic and aquaretic effects of intravenously infused calcium in preascitic human cirrhosis: physiopathological and clinical implications.

Authors:  G Sansoè; F Wong
Journal:  Gut       Date:  2007-02-15       Impact factor: 23.059

6.  Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver.

Authors:  A L Gerbes; V Gülberg; M Bilzer; M Vogeser
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

7.  Haemodynamic, renal sodium handling, and neurohormonal effects of acute administration of low dose losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis.

Authors:  N Girgrah; P Liu; J Collier; L Blendis; F Wong
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

8.  Sodium homeostasis with chronic sodium loading in preascitic cirrhosis.

Authors:  F Wong; P Liu; L Blendis
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

Review 9.  ANP-induced signaling cascade and its implications in renal pathophysiology.

Authors:  Franziska Theilig; Qingyu Wu
Journal:  Am J Physiol Renal Physiol       Date:  2015-01-28

10.  PDEs1-5 activity and expression in tissues of cirrhotic rats reveal a role for aortic PDE3 in NO desensitization.

Authors:  Rima Tahseldar-Roumieh; Thérèse Keravis; Suha Maarouf; Hélène Justiniano; Ramzi Sabra; Claire Lugnier
Journal:  Int J Exp Pathol       Date:  2009-09-15       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.